Immune checkpoint blockade has transformed cancer immunotherapy. The Wang laboratory was among the first to identify VISTA (V-domain Immunoglobulin Suppressor of T Cell Activation) as a promising immune checkpoint target for cancer therapy (1-4). Current multidisciplinary projects focus on the epigenetic and metabolic regulation of tumor-reactive T cells, CAR T cells, tumor-associated macrophages, and myeloid-derived suppressor cells (MDSCs). These studies integrate basic and clinical research, providing a strong training environment in translational cancer immunology.
We seek candidates with a recent PhD and with research experience in Biochemistry, Cell Biology, and Immunology to join our team. Interested applicants should submit a CV, a cover letter describing research interests, and contact information for three references to Dr. Li Lily Wang, wangl9@ccf.org.
References:
1. Le Mercier I, Chen W, Lines JL, Day M, Li J, Sergent P, Noelle RJ, Wang L (2014) VISTA regulates the development of protective anti-tumor immunity. Cancer Research, 74:1933-1944. PMC4116689
2. Xu W, Tạ MH, Malarkannan S, Wang L (2018) Review: The structure, expression, and function of immune-checkpoint protein VISTA as a critical regulator of anti-tumor immunity, autoimmunity, and inflammation. Cellular & Molecular Immunology. 2018 May 15(5):438-446 PMC6068175
3. Zhang K, Zakeri A, Alban T, Dong J, Ta HM, Zalavadia AH, Branicky A, Zhao H, Juric I, Husich H, Parthasarathy PB, Rupani A, Drazba JA, Chakraborty AA, Ching-Cheng Huang S, Chan T, Avril S, Wang LL. VISTA promotes the metabolism and differentiation of myeloid-derived suppressor cells by STAT3 and polyamine-dependent mechanisms. Cell Reports 2024 Jan 3;43(1):113661. doi: 10.1016/j.celrep.2023.113661. PMID: 38175754.
4. Hieu Minh Ta, Dia Roy, Keman Zhang, Tyler Alban, Ivan Juric, Juan Dong, Sachin Patnaik, Cassandra Gilmour, Amin Zakeri, Prerana B Parthasarathy, Amit Rupani, Yee Peng Phoon, Brian Gastman, Timothy Chan, Li Lily Wang. LRIG1 engages ligand VISTA and impairs tumor-specific CD8+ T cell responses. Science Immunology, 2024 May 17;9(95) PMID: 38758807 DOI: 10.1126/sciimmunol.adi7418
Principal Investigator: Lily Wang, PhD
Cleveland Clinic Research Department: Cancer Sciences (THOR)
Lab Research Topics:
Job Responsibilities:
Education:
Languages:
Work Experience:
Physical Requirements:
Personal Protective Equipment:
Preferred Application Materials:
All application materials should be submitted directly via email to Dr. Wang at wangl9@ccf.org
Keywords: Postdoc, Research, Immunology research
The policy of Cleveland Clinic Health System and its system hospitals (Cleveland Clinic Health System) is to provide equal opportunity to all of our caregivers and applicants for employment in our drug free environment. All offers of employment are followed by testing for controlled substances.
Cleveland Clinic Health System administers an influenza prevention program. You will be required to comply with this program, which will include obtaining an influenza vaccination on an annual basis or obtaining an approved exemption.
Decisions concerning employment, transfers and promotions are made upon the basis of the best qualified candidate without regard to color, race, religion, national origin, age, sex, sexual orientation, marital status, ancestry, status as a disabled or Vietnam era veteran or any other characteristic protected by law. Information provided on this application may be shared with any Cleveland Clinic Health System facility.
Please review the Equal Employment Opportunity poster.
Cleveland Clinic Health System is pleased to be an equal employment employer: Women / Minorities / Veterans / Individuals with Disabilities